AtaiBeckley Inc. Common Stock
ATAIATAI Life Sciences N.V. is a biotechnology company focused on developing psychedelics and other psychoactive compounds for mental health treatment. Based in the Netherlands, it aims to advance innovative therapies for psychiatric and neurological disorders through research and clinical development.
Company News
AtaiBeckley presented clinical and preclinical data at the 64th Annual ACNP Meeting in Nassau, Bahamas. The company's Phase 2b study of BPL-003 (mebufotenin benzoate) nasal spray for treatment-resistant depression showed significant rapid and sustained antidepressant effects at 8mg and 12mg doses compared to control, with good tolerability. The p...
AtaiBeckley Inc (NASDAQ: ATAI), formed from the merger of atai Life Sciences and Beckley Psytech, announced its 2026 outlook ahead of the J.P. Morgan Healthcare Conference. The company reported positive Phase 2b data for BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, with Phase 3 trials expected in Q2 2026. Additio...
Atai Life Sciences received FDA Breakthrough Therapy designation for BPL-003, a nasal spray targeting treatment-resistant depression. The company also raised approximately $130 million through a stock offering to advance its clinical programs.
atai Life Sciences plans to raise approximately $130 million through a public offering of 23,725,000 common shares at $5.48 per share, with proceeds intended to advance clinical development of product candidates and support corporate operations.
atai Life Sciences received a multi-year, milestone-driven grant from NIDA to develop novel non-hallucinogenic 5-HT2A/2C receptor agonists for treating opioid use disorder, focusing on innovative drug discovery approaches.
